Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.

17 Jan 2014

New study gives hope for novel glioblastoma multiforme treatment

A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme, the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease's aggressive and invasive nature.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

People with intermittent explosive disorder — a psychiatric illness characterized by impulsivity, hostility and recurrent aggressive outbursts — have elevated levels of two markers of systemic inflammation in their blood, according to a study involving nearly 200 subjects.

19 Dec 2013

Research suggests new way of treating asthma in obese people

Research conducted at Boston Children's Hospital indicates that obesity might cause asthma via factors in the immune system and suggests a new way of treating asthma in obese people—who often respond poorly to standard asthma medications. The study, conducted in a mouse model of asthma and in human lung fluid, was published online Dec. 15 by Nature Medicine.

16 Dec 2013

Study: Immune cells outside the brain may regulate propensity to develop depression

A new study shows that immune cells outside the brain may regulate propensity to develop depression. The data were presented today at the American College of Neuropsychopharmacology Annual Meeting.

13 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Childhood asthma, eczema linked to adolescent psychotic experiences

UK research indicates that children with asthma and eczema are significantly more likely to have psychotic experiences during adolescence, boosting a previously reported relationship between schizophrenia and atopic disorders.

28 Nov 2013

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema.

26 Nov 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Cocktail eradicates animals' brain tumors

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

26 Nov 2013

Type 2 diabetes cytokine elevation places teeth at risk

Scientists have detected significant differences in the cytokine and chemokine make up of gingival crevicular fluid taken from chronic periodontitis patients with uncontrolled Type 2 diabetes and those without.

21 Nov 2013

Women under 50 more likely to experience mental stress-induced ischemia

Researchers have found that women younger than 50 with a recent heart attack are more likely to experience restricted blood flow to the heart (myocardial ischemia) in response to psychological stress.

21 Nov 2013

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.

18 Nov 2013

Interleukin 6 News and Research

Further Reading

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

New study gives hope for novel glioblastoma multiforme treatment

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

Research suggests new way of treating asthma in obese people

Study: Immune cells outside the brain may regulate propensity to develop depression

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Scientists identify key factor for limiting inflammatory responses, particularly in skin

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Childhood asthma, eczema linked to adolescent psychotic experiences

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

Researchers identify new form of treatment for brain tumor

Cocktail eradicates animals' brain tumors

Type 2 diabetes cytokine elevation places teeth at risk

Women under 50 more likely to experience mental stress-induced ischemia

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News